News

Big Drug Stocks Have Rallied. Why an Analyst Says They Have More Room to Run.

Major drug stocks have gotten a lift in the past month, after trailing the overall market in 2020. There could be more upside in the group, which trades at a historically low valuation relative to the S&P 500 index.

Chris Schott, a drug analyst at J.P. Morgan, notes that big drug stocks trade on average for 13.6 times projected 2021 earnings against 21.5 times for the S&P 500 index.

The…

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News